ArticleHuman vaccines & immunotherapeutics2017
Persistence of antibodies 20 y after vaccination with a combined hepatitis A and B vaccine.
Article in Human vaccines & immunotherapeutics, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to 2 registered trials, which are not on this map. Cited by 22 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
An Open Single Centre Study to Evaluate the Long-term Antibody Persistence and Immune Memory Between 16 and 20 Years After the Primary Study HAB-028 (208127/021) in Which Healthy Adults Were Vaccinated With Twinrix Adult Following a Three-dose Schedule.
An Open Single Centre Study to Evaluate the Long-term Antibody Persistence and Immune Memory Between 16 and 20 Years After the Primary Study HAB-032 (208127/022) in Which Healthy Adults Were Vaccinated With Twinrix Adult Following a Three-dose Schedule.
Who cites it
22 citing papers in PubMed, 50 citations in OpenAlex.
- Modeling of antibody waning after heterologous boosting with Ad5-nCoV in individuals primed with two-dose CoronaVac previously.Human vaccines & immunotherapeutics · 2026Trial
- Persistence of HBsAg-specific antibodies and immune memory two to three decades after hepatitis B vaccination in adults.Journal of viral hepatitis · 2019Trial
- Impaired Immune Response to Primary but Not to Booster Vaccination Against Hepatitis B in Older Adults.Frontiers in immunology · 2018Trial
- Thirty years of hepatitis A epidemiology and vaccine studies: A narrative review of lessons learned in Alaska.Annals of epidemiology · 2026Review
- Traveling with chronic viral hepatitis.Tropical diseases, travel medicine and vaccines · 2026Review
- Prevalence of hepatitis B surface antibodies and hepatitis B exposure in Belgium: results from a nationwide population-based serosurvey.BMC infectious diseases · 2026Article
- Article
- Scientific approaches to defining HPV vaccine-induced protective immunity.International journal of cancer · 2025Review
- Hepatitis B virus as a risk factor for hepatocellular carcinoma: There is still much work to do.Liver research (Beijing, China) · 2024Review
- Exploring blood lipids-immunity associations following HBV vaccination: evidence from a large cross-sectional study.Frontiers in cellular and infection microbiology · 2024Article
- Rates of Seroprotection against Vaccine-Preventable Infectious Diseases in HIV-Exposed and -Unexposed Malawian Infants.Pathogens (Basel, Switzerland) · 2023Article
- Modeling long-term persistence after 8 years of hepatitis B booster vaccination in 5- to 15-year-old children.Human vaccines & immunotherapeutics · 2022Article
- SARS-CoV-2-Specific Antibody (Ab) Levels and the Kinetic of Ab Decline Determine Ab Persistence Over 1 Year.Frontiers in medicine · 2022Article
- Hepatitis A vaccination and its immunological and epidemiological long-term effects - a review of the evidence.Human vaccines & immunotherapeutics · 2021Review
- Long-Term Persistence of Antibody Response with Two Doses of Inactivated Hepatitis A Vaccine in Children.Infectious diseases and therapy · 2020Article
- The History of Hepatitis A.Clinical liver disease · 2020Review
- High-Yield Expression and Purification of Recombinant Influenza Virus Proteins from Stably-Transfected Mammalian Cell Lines.Vaccines · 2020Article
- Immunization against Hepatitis A.Cold Spring Harbor perspectives in medicine · 2019Review
- Role of Multivalency and Antigenic Threshold in Generating Protective Antibody Responses.Frontiers in immunology · 2019Review
- Comparison of anti-HBs persistence after hepatitis B vaccination on two-dose schedule and three-dose schedule among adults: results from a 12-year follow up study in China.Human vaccines & immunotherapeutics · 2019Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 4 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Vaccination is the most effective and well-tolerated method of conferring long-term protection against hepatitis A and B viruses (HAV; HBV). Long-term studies are required to characterize the duration of protection and need for boosters. Following primary immunization of 150 and 157 healthy adults with 3-doses of combined hepatitis A/hepatitis B vaccine (HAB; Twinrix™, GSK Vaccines, Belgium) at 0-1-6 months in 2 separate studies, we measured vaccine-induced antibody persistence against HAV and HBV annually for 20 y (Study A: NCT01000324; Study B: NCT01037114). Subjects with circulating anti-HAV antibodies < 15 mIU/mL or with anti-hepatitis B surface antigen < 10 mIU/mL were offered an additional monovalent hepatitis A and/or B vaccine dose (Havrix™/Engerix™-B, GSK Vaccines, Belgium). Applying the immunogenicity results from these studies, mathematical modeling predicted long-term persistence. After 20 y, 18 and 25 subjects in studies A and B, respectively, comprised the long-term according-to-protocol cohort for immunogenicity; 100% and 96.0% retained anti-HAV antibodies ≥ 15 mIU/mL, respectively; 94.4% and 92.0% had anti-HBs antibodies ≥ 10 mIU/mL, respectively. Between Years 16-20, 4 subjects who received a challenge dose of monovalent hepatitis A vaccine (N = 2) or hepatitis B vaccine (N = 2), all mounted a strong anamnestic response suggestive of immune memory despite low antibody levels. Mathematical modeling predicts that 40 y after vaccination ≥ 97% vaccinees will maintain anti-HAV ≥ 15 mIU/mL and ≥ 50% vaccinees will retain anti-HBs ≥ 10 mIU/mL. Immunogenicity data confirm that primary immunization with 3-doses of HAB induces persisting anti-HAV and anti-HBs specific antibodies in most adults for up to 20 y; mathematical modeling predicts even longer-term protection.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.